Figure 3.

High LTR Ability Defect and Impaired Myeloid Potential in E12.5 Fancg^−/− Pl and FL

(A) CD45.2 chimerism in the blood of primary recipients 20–24 weeks post injection of 5 × 10⁵ (circles) or 10⁶ (squares) WT (black) or Fancg^−/− (white) total FL cells.

(B) CD45.2 chimerism in primary recipients' blood 20–24 weeks post injection of 5 × 10⁵ (circles) or 10⁶ (squares) WT (black) or Fancg^−/− (white) Pl cells.

(C and D) Analysis of BM hematopoietic content of primary recipients transplanted with FL (C) or Pl (D), expressed as a percentage of CD45.2⁺ erythroid (TER119), myeloid (GR1), B lymphoid (B220), and T-lymphoid (CD4) cells. Circles, 5 × 10⁵ cells injected; squares, 1 × 10⁶ cells injected; black, WT FL or Pl cells; white, Fancg^−/− FL or Pl cells.

^∗∗∗p < 0.001, ^∗∗p < 0.01, ^∗p < 0.05; NS, not significant.